How long a patient with mds can usually live is related to the type of disease, the method of treatment, the effectiveness of the treatment, the patient’s own condition, and psychological and mental factors. Usually, the earlier the disease is detected, diagnosed and treated, the less impact mds will have on the patient’s life expectancy.
mds is myelodysplastic syndrome, which is clinically categorized into low-risk, intermediate-risk and high-risk groups. Patients in the low-risk and intermediate-risk groups have relatively slow disease progression, and after active and correct treatment, the prognosis is generally good, and the survival period of patients is relatively long, mostly more than 10 years.
However, for patients in the high-risk group, as this type of disease tends to progress more rapidly, it may lead to abnormal hematopoietic function, and in severe cases, patients may be transformed into acute myeloid leukemia. Therefore, the prognosis of this type of disease is generally relatively poor, and the survival period will be shortened accordingly.
Therefore, it is recommended that patients with mds undergo regular treatment as early as possible to minimize the adverse effects of the disease on the body.